文献速递肿瘤 PET/CT核素与放射性配体治疗

18F-PSMA-1007 PET/CT评估转移性肾细胞癌系统治疗反应的初步结果

18F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-12-28

本研究纳入11例接受酪氨酸激酶抑制剂或检查点抑制剂治疗的转移性肾细胞癌患者,在治疗前及治疗8周后行18F-PSMA-1007 PET/CT,分别按改良PERCIST和RECIST 1.1评估反应。PSMA-PET与CT分类仅2例一致,CT判为稳定病的9例中PET重新分类为完全缓解3例、部分缓解3例、进展1例、稳定2例。提示PSMA-PET可能为CT稳定病患者提供更精确的疗效评估。

要点

  • PSMA-PET与RECIST 1.1评估结果高度不一致,仅2例分类一致。
  • CT判为稳定病的患者中,PSMA-PET可区分出缓解与进展。
  • PSMA-PET可能弥补早期疗效生物标志物的缺失。

核心结论

  • 在转移性肾细胞癌系统治疗中,PSMA-PET观察到异质性病程,与RECIST 1.1结果差异很大。
  • 鉴于缺乏早期疗效生物标志物,PSMA-PET可能实现更精确的疗效评估,尤其对CT判为稳定病的患者。

研究设计与样本

  • 前瞻性初步研究,纳入11例接受酪氨酸激酶抑制剂或检查点抑制剂治疗的转移性肾细胞癌患者。
  • 在系统治疗开始前及治疗开始后8周行18F-PSMA-1007 PET/CT。
  • 分别用改良PERCIST评分系统评估PSMA-PET的SUVmean变化,用RECIST 1.1评估CT反应,并进行比较。

主要发现

  • 基线时所有患者至少有一个PSMA高摄取病灶。
  • 随访PET2时,完全缓解3例、部分缓解3例、稳定病4例、进展病1例。
  • 按RECIST 1.1,部分缓解1例、稳定病9例、进展病1例。
  • PSMA-PET与CT分类一致仅2例(均为稳定病)。
  • CT判为稳定病的9例中,PSMA-PET分类为完全缓解3例、部分缓解3例、进展病1例、稳定病2例。

关键数值与推荐

  • PSMA-PET完全缓解定义为治疗后所有靶病灶无任何摄取。
  • PSMA-PET部分缓解定义为总SUVmean下降超过30%。
  • PSMA-PET进展病定义为出现新的PET阳性病灶或总SUVmean增加超过30%。
  • PSMA-PET稳定病定义为总SUVmean变化在±30%以内。
  • CT反应评估采用RECIST 1.1标准。

临床怎么用

  • 对CT判为稳定病的转移性肾细胞癌患者,可考虑PSMA-PET进一步区分缓解、稳定或进展。
  • PSMA-PET可能辅助个体化治疗管理,尤其当血清生化无法预测疗效时。

局限性

  • 样本量仅11例,为初步结果。
  • PSMA-PET反应标准采用改良PERCIST评分系统,非标准验证标准。
  • 未报告生存终点或长期随访数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Tyrosine kinase (TKI) and checkpoint inhibitors (CI) prolonged overall survival in metastatic renal cell carcinoma (mRCC). Early prediction of treatment response is highly desirable for the individualization of patient management and improvement of therapeutic outcome; however, serum biochemistry is unable to predict therapeutic efficacy. Therefore, we compared 18F-PSMA-1007 PET imaging for response assessment in mRCC patients undergoing TKI or CI therapy compared to CT-based response assessment as the current imaging reference standard. METHODS: 18F-PSMA-1007 PET/CT was performed in mRCC patients prior to initiation of systemic treatment and 8 weeks after therapy initiation. Treatment response was evaluated separately on 18F-PSMA-PET and CT. Changes on PSMA-PET (SUVmean) were assessed on a per patient basis using a modified PERCIST scoring system. Complete response (CRPET) was defined as absence of any uptake in all target lesions on posttreatment PET. Partial response (PRPET) was defined as decrease in summed SUVmean of > 30%. The appearance of new, PET-positive lesions or an increase in summed SUVmean of > 30% was defined as progressive disease (PDPET). A change in summed SUVmean of ± 30% defined stable disease (SDPET). RECIST 1.1 criteria were used for response assessment on CT. Results of radiographic response assessment on PSMA-PET and CT were compared. RESULTS: Overall, 11 mRCC patients undergoing systemic treatment were included. At baseline PSMA-PET1, all mRCC patients showed at least one PSMA-avid lesion. On follow-up PET2, 3 patients showed CRPET, 3 PRPET, 4 SDPET, and 1 PDPET. According to RECIST 1.1, 1 patient showed PRCT, 9 SDCT, and 1 PDCT. Overall, concordant classifications were found in only 2 cases (2 SDCT + PET). Patients with CRPET on PET were classified as 3 SDCT on CT using RECIST 1.1. By contrast, the patient classified as PRCT on CT showed PSMA uptake without major changes during therapy (SDPET). However, among 9 patients with SDCT on CT, 3 were classified as CRPET, 3 as PRPET, 1 as PDPET, and only 2 as SDPET on PSMA-PET. CONCLUSION: On PSMA-PET, heterogeneous courses were observed during systemic treatment in mRCC patients with highly diverging results compared to RECIST 1.1. In the light of missing biomarkers for early response assessment, PSMA-PET might allow more precise response assessment to systemic treatment, especially in patients classified as SD on CT.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Mittlmeier LM, Unterrainer M, Rodler S, et al. 18F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results. Eur J Nucl Med Mol Imaging. 2020. PMID: 33369689. doi:10.1007/s00259-020-05165-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。